Trials / Unknown
UnknownNCT04907344
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
A Multicenter, Open, Randomized Controlled Study of Camrelizumab+ Nab-paclitaxel + Carboplatin Versus Nab-paclitaxel + Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in Combination With Nab-Paclitaxel and carboplatin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | IV infusion |
| DRUG | Nab-Paclitaxel | IV infusion |
| DRUG | Carboplatin | IV infusion |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
- First posted
- 2021-05-28
- Last updated
- 2021-05-28
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04907344. Inclusion in this directory is not an endorsement.